Mainz Biomed BV
Mainz Biomed N.V. develops and sells in-vitro diagnostic (IVD) tests for the early detection of cancer in the United States and Europe. It offers ColoAlert, a colorectal cancer diagnostic molecular genetic stool test. The company also develops PancAlert, a stool-based screening test for the detection of pancreatic cancer. In addition, it operates a clinical diagnostic laboratory; and distributes … Read more
Mainz Biomed BV (MYNZ) - Net Assets
Latest net assets as of June 2025: $2.52 Million USD
Based on the latest financial reports, Mainz Biomed BV (MYNZ) has net assets worth $2.52 Million USD as of June 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($9.80 Million) and total liabilities ($7.28 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $2.52 Million |
| % of Total Assets | 25.73% |
| Annual Growth Rate | N/A |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | 86.45 |
Mainz Biomed BV - Net Assets Trend (2019–2024)
This chart illustrates how Mainz Biomed BV's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Mainz Biomed BV (2019–2024)
The table below shows the annual net assets of Mainz Biomed BV from 2019 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | $6.05 Million | +86.09% |
| 2023-12-31 | $3.25 Million | -76.95% |
| 2022-12-31 | $14.10 Million | +121.60% |
| 2021-12-31 | $6.36 Million | +332.03% |
| 2020-12-31 | $-2.74 Million | -40.57% |
| 2019-12-31 | $-1.95 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Mainz Biomed BV's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 8661071900.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $922.12K | 15.25% |
| Other Comprehensive Income | $27.04 Million | 447.17% |
| Other Components | $69.07 Million | 1142.22% |
| Total Equity | $6.05 Million | 100.00% |
Mainz Biomed BV Competitors by Market Cap
The table below lists competitors of Mainz Biomed BV ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
ACKERMANS - Dusseldorf Stock Exchang
DU:B3K
|
$2.66 Million |
|
Global Sweeteners Holdings Limited
F:3GS
|
$2.66 Million |
|
HG Holdings Inc
OTCQB:STLY
|
$2.66 Million |
|
OMG Group Ltd
AU:OMG
|
$2.66 Million |
|
Trench Metals Corp
V:TMC
|
$2.66 Million |
|
Hunter Capital AB (publ)
F:2DD0
|
$2.66 Million |
|
FBS Global Limited Ordinary Shares
NASDAQ:FBGL
|
$2.66 Million |
|
WIMFARM S.A. EO 1-
F:6WW
|
$2.66 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Mainz Biomed BV's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 3,249,226 to 6,046,543, a change of 2,797,317 (86.1%).
- Net loss of 21,650,663 reduced equity.
- New share issuances of 13,764,717 increased equity.
- Other comprehensive income increased equity by 6,204,172.
- Other factors increased equity by 4,479,091.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-21.65 Million | -358.07% |
| Share Issuances | $13.76 Million | +227.65% |
| Other Comprehensive Income | $6.20 Million | +102.61% |
| Other Changes | $4.48 Million | +74.08% |
| Total Change | $- | 86.09% |
Book Value vs Market Value Analysis
This analysis compares Mainz Biomed BV's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.12x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2019-12-31 | $-0.17 | $0.76 | x |
| 2020-12-31 | $-0.49 | $0.76 | x |
| 2021-12-31 | $0.88 | $0.76 | x |
| 2022-12-31 | $1.00 | $0.76 | x |
| 2023-12-31 | $0.20 | $0.76 | x |
| 2024-12-31 | $6.24 | $0.76 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Mainz Biomed BV utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -358.07%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -2421.80%
- • Asset Turnover: 0.07x
- • Equity Multiplier: 2.19x
- Recent ROE (-358.07%) is below the historical average (-256.47%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2019 | 0.00% | -340.11% | 0.39x | 0.00x | $-762.03K |
| 2020 | 0.00% | -118.91% | 0.73x | 0.00x | $-312.74K |
| 2021 | -183.77% | -2024.79% | 0.06x | 1.58x | $-12.33 Million |
| 2022 | -187.66% | -4992.24% | 0.03x | 1.44x | $-27.86 Million |
| 2023 | -809.29% | -2936.50% | 0.06x | 4.74x | $-26.62 Million |
| 2024 | -358.07% | -2421.80% | 0.07x | 2.19x | $-22.26 Million |
Industry Comparison
This section compares Mainz Biomed BV's net assets metrics with peer companies in the Diagnostics & Research industry.
Industry Context
- Industry: Diagnostics & Research
- Average net assets among peers: $914,015,556
- Average return on equity (ROE) among peers: -22.24%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Mainz Biomed BV (MYNZ) | $2.52 Million | 0.00% | 2.89x | $2.66 Million |
| Agilent Technologies Inc (A) | $4.08 Billion | 3.46% | 0.65x | $31.80 Billion |
| Amer Bio Medica (ABMC) | $3.38 Million | -26.64% | 1.08x | $3.55K |
| ADCNF (ADCNF) | $1.77 Billion | 2.65% | 1.64x | $172.01 Million |
| Advanced Biomed Inc. Common Stock (ADVB) | $3.48 Billion | 0.00% | 0.87x | $1.68 Million |
| ANGLE plc (ANPCF) | $18.44 Million | -77.14% | 0.38x | $34.42 Million |
| SeqLL Inc. (ATLN) | $8.18 Million | -45.26% | 0.31x | $35.63K |
| Avricore Health Inc (AVCRF) | $2.20 Million | -79.50% | 0.04x | $3.22 Million |
| Aspira Womens Health Inc (AWH) | $-11.46 Million | 0.00% | 0.00x | $664.47K |
| Biodesix Inc (BDSX) | $-198.03 Million | 0.00% | 0.00x | $50.38 Million |
| bioAffinity Technologies, Inc. (BIAF) | $-15.79 Million | 0.00% | 0.00x | $5.08 Million |